SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (Nasdaq:NSTR) today reported that planned investments in its cortical stimulation platform and execution of its four ongoing clinical trials resulted in a net loss of $5.4 million for the quarter ended September 30, 2006 compared to a net loss of $3.6 million for the quarter ended September 30, 2005. The Company also reported cash, cash equivalents and investments of $109.4 million at September 30, 2006 compared to $20.2 million at December 31, 2005.
